INNOVA CAPTAB
|
|
BOM : 544067     NSE : INNOVACAP     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : NA |
Jan 23,2025 |
Price(EOD): ₹ 1,070.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 6,125.26 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
INNOVA CAPTAB | -3.6% | 1.6% | 99.9% |
SUN PHARMACEUTICAL INDUSTRIES | 2% | -0.9% | 31.9% |
CIPLA | -0.3% | -2.5% | 7.9% |
DR REDDYS LABORATORIES | -0.5% | -3.3% | 14% |
ZYDUS LIFESCIENCES | -1% | 0.6% | 39.1% |
DIVIS LABORATORIES | -1.6% | -0.4% | 57.3% |
MANKIND PHARMA | -1.3% | -16.2% | 19.6% |
TORRENT PHARMACEUTICALS | -0.4% | -7.4% | 28.3% |
LUPIN | 1.9% | -1% | 47.6% |
FUNDAMENTAL ANALYSIS OF INNOVA CAPTAB
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF INNOVA CAPTAB
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
51.79
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 118.33 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 7.38
P/B Calculated based on Book Value of Rs 830.89 Cr
[Latest Year - Mar2024 - Consolidated Results ] 5.2
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,177.59 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
33469% 13524% - |
SHARE PRICE MOMENTUM OF INNOVA CAPTAB
INNOVA CAPTAB vs SENSEX
DEBT OF INNOVA CAPTAB
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.33 0.88 0.84 0.68 |
0.29 0.85 0.95 0.7 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF INNOVA CAPTAB
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF INNOVA CAPTAB
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
8.13% 17.92% 19.08% 18.75% |
12.46% 22.86% 55.08% 52.82% |
QtrlyTrend |
8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
INNOVA CAPTAB related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 1.4% | -2.1% | 32.5% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE MIDSMALLCAP | -1.4% | -6.4% | 16.1% |
S&P BSE SMALL CAP | -2% | -6.5% | 16.6% |
You may also like the below Video Courses
FAQ about INNOVA CAPTAB
Is INNOVA CAPTAB good for long term investment?
As on Jan 23,2025, the Fundamentals of INNOVA CAPTAB look Strong and hence it may be good for long term investment! See Financial Performance of INNOVA CAPTAB . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is INNOVA CAPTAB UnderValued or OverValued?
As on Jan 23,2025, INNOVA CAPTAB is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of INNOVA CAPTAB ?
As on Jan 23,2025, the Intrinsic Value of INNOVA CAPTAB is Rs. 5.52 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 3.19
Fair Value [Median EV / Sales Model] : Rs. 7.86
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of INNOVA CAPTAB : Rs. 5.52
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.